Search the Newsreel

Enlivex Ltd. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing by Enlivex Ltd. (NASDAQ: ENLV) on August 14, 2026, which was a Notice of Effectiveness for an F-3 form. The filing was accepted by the SEC EDGAR system on the same day. The article also provides an …

Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake

OrbiMed Advisors LLC and OrbiMed Capital LLC have disclosed a combined 5% ownership stake in Lexeo Therapeutics, Inc. (LXEO). OrbiMed Advisors LLC holds 4.1% of the common stock with shared voting and dispositive power, while OrbiMed Capital LLC holds 1.0% with sole voting and …

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.9% in Inhibikase Therapeutics, Inc. (IKT) through warrants. This stake, totaling 10,320,875 shares, is primarily held by the Master Fund through various pre-funded and common warrants, …

Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds

Two Seas Capital group, including Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi, has reported a 9.1% beneficial ownership stake in Nektar Therapeutics (NKTR). As of June 30, 2026, they collectively own 3,092,234 shares of common stock through investment funds, …

Edgewise Therapeutics (NASDAQ:EWTX) CEO Kevin Koch Sells 17,971 Shares of Stock

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock

Maze Therapeutics' CMO, Harold Bernstein, sold 16,142 shares of company stock worth $445,680.62 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 50%. This follows a previous sale of 14,609 shares in July. Despite the insider selling and the company's ongoing unprofitability with …

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells 6,522 Shares

Edgewise Therapeutics CMO Joanne Donovan recently sold 6,522 shares of EWTX stock for $285,989.70 to cover tax withholding obligations on vested equity awards, reducing her holdings by 36.1%. Despite this insider sale and a quarterly earnings miss, the company's shares rose 2.3%, and analysts …

Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares

Edgewise Therapeutics (NASDAQ:EWTX) insider Alan Russell sold 5,901 shares of the company's stock on August 12th, 2026, totaling approximately $258,051. This sale was conducted to cover tax withholding obligations related to vested equity awards. Despite this insider selling, analysts maintain a "Moderate Buy" consensus …

Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, reported equity transactions on August 12, 2026, which included exercising Restricted Stock Units and selling 5,901 shares to cover tax withholding obligations. Additionally, Russell received new equity awards comprising 32,500 RSUs and a stock option for …

Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock

Edgewise Therapeutics General Counsel John Moore sold 5,016 shares of EWTX stock worth $219,801.12 to cover tax withholding obligations from vested equity awards, reducing his direct ownership by 22.08%. The company's stock is trading near its 52-week high, and despite missing recent earnings expectations, …

Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option

Edgewise Therapeutics (EWTX) has granted its CFO, Michael Nofi, 24,375 Restricted Stock Units (RSUs) and an option for 48,750 shares of common stock. The RSUs vest in four equal annual installments starting August 12, 2027, and the stock options vest monthly over 48 months …

RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares

RA Capital Management, L.P. and its affiliated parties have reported a 7.8% stake in Edgewise Therapeutics, Inc. (EWTX), totaling 8,392,730 shares of common stock. This ownership is held by RA Capital Healthcare Fund, L.P., with RA Capital having shared voting and dispositive power over …

Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO

Edgewise Therapeutics reported that its Chief Business Officer, Derakhshan Behrad, received equity awards comprising 50,000 Restricted Stock Units (RSUs) and a stock option for 100,000 shares. Behrad also had 5,781 and 7,500 RSUs convert into common stock on August 12, 2026, and subsequently sold …

United Therapeutics (UTHR) CEO Rothblatt exercises 9,500 options and sells 9,500 shares via 10b5-1 plan

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 common shares for weighted-average prices between $500 and $513 per share. These transactions were conducted on August 13, 2026, under …

Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 7.3% in SAB Biotherapeutics (SABS). The Master Fund directly holds 6,627,501 shares, representing this percentage based on 90,986,368 shares outstanding as of August 3, 2026. All …

Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake

ADAR1 Capital Management, LLC and its manager Daniel Schneeberger have reported a beneficial ownership of 9,559,979 shares of Ovid Therapeutics (OVID) common stock, which represents 5.1% of the class. This includes shares held by various affiliated entities and warrants. The filing also notes an …

RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants

RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, has reported a beneficial ownership of 9.99% in Ovid Therapeutics (OVID) as of June 30, 2026. This stake, totaling 19,549,271 shares, includes direct common stock holdings and shares underlying pre-funded and Series B …

Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes

Actuate Therapeutics CEO Daniel M. Schmitt had 272,056 restricted stock units (RSUs) vest on August 14, 2026. To cover federal and state tax obligations, 120,521 shares of common stock were withheld by the company at a per-share value of $1.01. This transaction is consistent …

Perceptive Advisors discloses 4.9% stake in Spyre Therapeutics (SYRE) via Master Fund

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a 4.9% beneficial ownership stake in Spyre Therapeutics (SYRE) through a SCHEDULE 13G/A filing. This stake amounts to 4,319,496 shares of common stock, based on 88,173,762 shares outstanding …

Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership

RA Capital Management, L.P., and its affiliates, including Peter Kolchinsky and Rajeev Shah, have filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Atrium Therapeutics (RNA) common stock as of June 30, 2026. This indicates they hold no shares and possess no voting …

Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in Inhibikase Therapeutics (IKT), totaling 5,810,487 shares as of June 30, 2026. This stake includes 3,108,624 shares acquirable through convertible securities within sixty days. The …

Vivos Therapeutics Q2 revenue up 35% YoY; gross margin expands to 57%

CAPRICOR THERAPEUTICS, INC. 2026: Revenue $14.08M, EPS ($0.7) — 10-Q Summary

Capricor Therapeutics reported its 2026 quarterly results, showing a significant increase in revenue to $14.08M from $5.67M a year prior, alongside an increased net loss of ($40.73M) and a diluted loss per share of ($0.7). The company is progressing with its BLA for Deramiocel, …

Appili Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan

Maze Therapeutics' President, R&D & CMO, Harold Bernstein, exercised 16,142 stock options and subsequently sold the resulting shares on August 13, 2026, under a Rule 10b5-1 trading plan. The options were exercised at $10.42 per share, and the common shares were sold at a …

Protagonist Therapeutics stock hits all-time high at 155.01 USD By Investing.com

Protagonist Therapeutics (PTGX) stock reached an all-time high of $155.01, just shy of its 52-week high, with a market capitalization of $10 billion, representing a 175.66% increase over the past year. This surge is attributed to growing investor confidence and positive developments in its …

Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake

Paradigm BioCapital-related entities and Senai Asefaw, M.D. have reported beneficial ownership in Lexeo Therapeutics, Inc. (LXEO) via a Schedule 13G/A filing. Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw each beneficially own 4,175,382 shares, representing 5.3% of the class, while …

RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap

RA Capital Management, L.P. and its affiliates reported a 9.99% beneficial ownership in Rani Therapeutics Holdings, Inc. (RANI) Class A common stock as of June 30, 2026. This ownership is capped at 11,530,414 shares due to "Beneficial Ownership Blockers" in pre-funded and common warrants, …

RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap

RA Capital Management, L.P. and its affiliated reporting persons have reported a 9.99% beneficial ownership stake in Karyopharm Therapeutics Inc. (KPTI) as of June 30, 2026. This stake, totaling 2,302,504 shares, is held through RA Capital Healthcare Fund, L.P., and is capped at 9.99% …

Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles

Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive

Nantahala Capital Management, alongside Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 2,807,830 shares, representing 9.99% of Unicycive Therapeutics, Inc. common stock as of June 30, 2026. This holding includes 1,406,383 shares acquirable through convertible securities within 60 days, with …

Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have reported a 9.99% beneficial ownership stake in Unicycive Therapeutics, Inc. (UNCY). This stake, detailed in an amended Schedule 13G filing, comprises 4,856,259 shares, which includes common stock and shares convertible from …

Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes

Frazier Life Sciences Public Fund, L.P. has reported a 5.6% ownership stake in Allogene Therapeutics (ALLO), holding 19,445,046 shares. Other affiliated Frazier funds also hold additional stakes, bringing the total reported beneficial ownership by various Frazier entities and individuals to a significant portion of …

Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A

An amended Schedule 13G filing for Tango Therapeutics (TNGX) reveals that Nextech Crossover I SCSp, Nextech Crossover I GP S.a r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo now report 0 beneficial shares, equating to 0.0% ownership as of June 30, 2026. …

Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital

Lynx1 Capital Management LP and Weston Nichols have disclosed a 6.5% beneficial ownership stake in Stoke Therapeutics (STOK), totaling 4,038,404 common shares. This ownership is based on 62,240,347 shares outstanding as of March 31, 2026, with the reporting persons holding shared voting and dispositive …

Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G

Caligan Partners LP and David Johnson have filed an amended Schedule 13G, disclosing beneficial ownership of 7,967,207 shares of SAB Biotherapeutics, Inc. (SABS) common stock, representing an 8.8% stake. This ownership is based on 90,986,368 shares outstanding as of August 3, 2026. Both Caligan …